We found that diabetes comorbidity and corticosteroids therapy, as well as the SpO2, CRP, PCT, and fibrinogen levels, affect the prolonged production of NAbs against SARS-CoV-2 in individuals who recover from COVID-19. This evidence concerns the gene CRP and diabetes mellitus.